[
  {
    "ts": null,
    "headline": "Labcorp Holdings Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Labcorp Holdings Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=40b2366f214ded3edd7b05a4d31ac8c2402db11703b16700fbcb956e9a2b6bbe",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741799220,
      "headline": "Labcorp Holdings Inc. stock underperforms Wednesday when compared to competitors",
      "id": 133254823,
      "image": "",
      "related": "LH",
      "source": "MarketWatch",
      "summary": "Labcorp Holdings Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=40b2366f214ded3edd7b05a4d31ac8c2402db11703b16700fbcb956e9a2b6bbe"
    }
  },
  {
    "ts": null,
    "headline": "Labcorp to acquire certain assets of Opko Health’s BioReference Health",
    "summary": "Labcorp (LH) and OPKO Health (OPK) announced earlier on Tuesday that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. Through this transaction, Labcorp will acquire BioReference Health’s laboratory testing businesses focused on oncology and oncology-related clinical testing services across the United States. This transaction includes certain customer accounts and other operating assets. When complete, the t",
    "url": "https://finnhub.io/api/news?id=7779069e101b92a0f7cb8d4a798953cd6ab1fe8d5e7bcbb642d7be15904c4119",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741795823,
      "headline": "Labcorp to acquire certain assets of Opko Health’s BioReference Health",
      "id": 133191398,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LH",
      "source": "Yahoo",
      "summary": "Labcorp (LH) and OPKO Health (OPK) announced earlier on Tuesday that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. Through this transaction, Labcorp will acquire BioReference Health’s laboratory testing businesses focused on oncology and oncology-related clinical testing services across the United States. This transaction includes certain customer accounts and other operating assets. When complete, the t",
      "url": "https://finnhub.io/api/news?id=7779069e101b92a0f7cb8d4a798953cd6ab1fe8d5e7bcbb642d7be15904c4119"
    }
  },
  {
    "ts": null,
    "headline": "Truist remains bullish on Labcorp after ‘another nice strategic acquisition’",
    "summary": "Truist analyst David MacDonald notes Labcorp (LH) announced that the company has reached an agreement to acquire oncology-focused lab testing assets from BioReference Health (OPK) for $192.5M, with an additional earnout of up to $32.5M. The deal is expected to close in the second half of 2025, meets the company’s financial/strategic criteria and is expected to be accretive to earnings year one. The deal continues the strong M&A momentum from 2024, and Truist expects the additional BioReference a",
    "url": "https://finnhub.io/api/news?id=186c40af9ebfaedcc9c5023928fc513518f5a7ad9ec5361c5bf18e8ff6c09d7a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741791960,
      "headline": "Truist remains bullish on Labcorp after ‘another nice strategic acquisition’",
      "id": 133191400,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LH",
      "source": "Yahoo",
      "summary": "Truist analyst David MacDonald notes Labcorp (LH) announced that the company has reached an agreement to acquire oncology-focused lab testing assets from BioReference Health (OPK) for $192.5M, with an additional earnout of up to $32.5M. The deal is expected to close in the second half of 2025, meets the company’s financial/strategic criteria and is expected to be accretive to earnings year one. The deal continues the strong M&A momentum from 2024, and Truist expects the additional BioReference a",
      "url": "https://finnhub.io/api/news?id=186c40af9ebfaedcc9c5023928fc513518f5a7ad9ec5361c5bf18e8ff6c09d7a"
    }
  },
  {
    "ts": null,
    "headline": "Labcorp to buy Opko unit’s cancer test assets for up to $225M",
    "summary": "Labcorp will acquire BioReference Health's oncology diagnostics operations as the lab company works to expand in high-growth testing areas.",
    "url": "https://finnhub.io/api/news?id=c170c78fd3332355e94976415221f2359caebc43d38ceca48576952e6e412b76",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741776617,
      "headline": "Labcorp to buy Opko unit’s cancer test assets for up to $225M",
      "id": 133191401,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LH",
      "source": "Yahoo",
      "summary": "Labcorp will acquire BioReference Health's oncology diagnostics operations as the lab company works to expand in high-growth testing areas.",
      "url": "https://finnhub.io/api/news?id=c170c78fd3332355e94976415221f2359caebc43d38ceca48576952e6e412b76"
    }
  }
]